Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.59 |
| ▸ | CCR5 | P51681 | 1/20 | 0.59 |
| ▸ | CCR8 | P51685 | 1/20 | 0.59 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | VHL | P40337 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9426089 | 0.85 | KDM4E (0.36) | CYP2A6KDM4EMEN1NOS3NOS1 | |
| SCHEMBL31754560 | 0.83 | GRM5 (0.51) | CCR1CCR5CCR8METAP2GRM5 | |
| SCHEMBL198098 | 0.81 | CCR1 (0.81) | CCR1CCR5CCR8METAP2CYP2A6 | |
| SCHEMBL91455 | 0.79 | — | — | |
| SCHEMBL30078627 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL30496256 | 0.77 | UHRF1 (0.48) | CCR1CCR5CCR8METAP2CYP2A6 | |
| Hydrochloric Acid SCHEMBL30478264 | 0.77 | UHRF1 (0.48) | CCR1CCR5CCR8METAP2CYP2A6 | |
| SCHEMBL29397106 | 0.77 | CCR1 (1.00) | CCR1CCR5CCR8METAP2CYP2A6 | |
| SCHEMBL181893 | 0.77 | CCR1 (1.00) | CCR1CCR5CCR8METAP2CYP2A6 | |
| SCHEMBL24683565 | 0.76 | CCR1 (0.71) | CCR1CCR5CCR8METAP2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018134847-A1 | IMMUNOSUPPRESSIVE AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018134847-A1 | IMMUNOSUPPRESSIVE AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-07-26 | — | — | WO | disclosed |
| EP-2868661-B1 | BIPYRIDYL TRIAZOLE RARE EARTH COMPLEX AND PREPARATION PROCESS THEREFOR | GUANGDONG SYNYOO NEW MATERIAL CO LTD (CN) | 2016-11-09 | — | — | EP | disclosed |
| EP-2868661-A1 | BIPYRIDYL TRIAZOLE RARE EARTH COMPLEX AND PREPARATION PROCESS THEREFOR | Guangdong Synyoo New Material Co. Ltd. (CN) | 2015-05-06 | — | — | EP | disclosed |
| US-8853399-B1 | Bipyridine triazole type rare earth complex and preparation method thereof | GUANGDONG SYNYOO NEW MATERIAL CO., LTD. (CN) | 2014-10-07 | — | — | US | disclosed |
| US-8853399-B1 | Bipyridine triazole type rare earth complex and preparation method thereof | GUANGDONG SYNYOO NEW MATERIAL CO., LTD. (CN) | 2014-10-07 | — | — | US | disclosed |
| US-20140288305-A1 | BIPYRIDINE TRIAZOLE TYPE RARE EARTH COMPLEX AND PREPARATION METHOD THEREOF | GUANGDONG SYNYOO NEW MATERIAL CO., LTD. (CN) | 2014-09-25 | — | — | US | disclosed |
| US-20140288305-A1 | BIPYRIDINE TRIAZOLE TYPE RARE EARTH COMPLEX AND PREPARATION METHOD THEREOF | GUANGDONG SYNYOO NEW MATERIAL CO., LTD. (CN) | 2014-09-25 | — | — | US | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | CCR1 199/4885CCR5 51/4885CCR8 1839/4885 |
| US-20140288305-A1 | BIPYRIDINE TRIAZOLE TYPE RARE EARTH COMPLEX AND PREPARATION METHOD THEREOF | LAS1L, RUVBL1, PDCD2L | CCR1 3156/4885CCR5 3199/4885CCR8 4475/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | CCR1 199/4885CCR5 51/4885CCR8 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.